



1645

Docket No. 1758-4036US2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): MINETTI, C, et al.

Group Art Unit: 1645

**RECEIVED**

Serial No.: 09/120,044

Examiner: S. Devi

JUL 17 2001

Filed: July 21, 1998

TECH CENTER 1600/2900

For: MODIFIED IMMUNOGENIC PNEUMOLYSIN COMPOSITIONS AS VACCINES

**CERTIFICATE OF MAILING (37 C.F.R. §1.8(a))**Commissioner for Patents  
Washington, D.C. 20231

Sir:

I hereby certify that the attached:

1. Amendment and Response to Official Action (14 pages); and
2. Return Postcard.

along with any paper(s) referred to as being attached or enclosed and this Certificate of Mailing are being deposited with the United States Postal Service on date shown below with sufficient postage as first-class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C., 20231.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.Dated: July 9, 2001By: Darryl H. Steensma  
Darryl H. Steensma  
Registration No. 43,155Correspondence Address:MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile



RECEIVED

JUL 17 2001

TECH CENTER 1600/2900

PATENT  
DOCKET NO. 1758-4036US2

*Handwritten:* #29/6  
7/18/01  
Not

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : MINETTI, C. et al. Art Unit : 1645  
Serial No : 09/120,044 Examiner : S. Devi  
Filed : July 21, 1998  
For: : MODIFIED IMMUNOGENIC PNEUMOLYSIN  
COMPOSITIONS AS VACCINES

AMENDMENT AND RESPONSE TO OFFICIAL ACTION

COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

In response to the Official Action mailed April 10, 2001, applicants present the following amendment and remarks. Claims 1-15, 27-26, and 31-34 are pending in the application. Applicants herewith cancel the pending claims and add new claims 35-64.

AMENDMENT

Please ~~cancel~~ claims 1-15, 22-26, and 31-34.

Please ~~add~~ the following claims.

- Sub P1*  
*25*
35. A pneumolysin polypeptide comprising SEQ ID NO: 3, wherein the polypeptide is modified, refolded and has attenuated hemolytic activity, and wherein the polypeptide has at least one amino acid substitution in the region comprising amino acids 1 to 257.